La Jolla Pharmaceutical Co (LJPC.OQ)
23 Feb 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|50||2014||Chairman of the Board|
|57||2012||President, Chief Executive Officer, Secretary, Director|
|62||2015||Chief Financial Officer|
|63||2017||Chief Operating Officer|
|48||2017||Chief Scientific Officer|
- BRIEF-La Jolla Pharmaceutical Q4 Loss Per Share $1.74
- BRIEF-La Jolla Pharmaceutical Announces Treatment Of First Patient In Giapreza Pediatric Study
- BRIEF-La Jolla Pharmaceutical Says Established Wholesale Acquisition Cost of Single-Dose Vial Of Giapreza At $1,500/ Vial
- BRIEF-Broadfin Capital Reports 5 Percent Passive Stake In La Jolla Pharmaceutical - SEC Filing
- BRIEF-La Jolla Pharmaceutical Says Cash Resources Are Expected To Fund Co Into Second Half Of 2018